Last reviewed · How we verify
CT-P42
CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.
At a glance
| Generic name | CT-P42 |
|---|---|
| Sponsor | Celltrion |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CT-P42 is a PD-L1 checkpoint inhibitor developed as a biosimilar candidate to atezolizumab. By blocking the PD-L1/PD-1 axis, it prevents tumor cells from suppressing T-cell mediated immunity, thereby reactivating the body's anti-tumor immune response. This mechanism is used across multiple cancer types where PD-L1 expression is associated with immune evasion.
Approved indications
- Non-small cell lung cancer
- Urothelial carcinoma
- Triple-negative breast cancer
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |